Saltar al contenido
Merck

R2408

Sigma-Aldrich

Rosiglitazone

≥98% (HPLC), powder, PPARγ agonist

Sinónimos:

Rosiglitazone, 5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula lineal:
C18H19N3O3S
Número de CAS:
Peso molecular:
357.43
Número MDL:
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
NACRES:
NA.77

product name

Rosiglitazone, ≥98% (HPLC)

Nivel de calidad

Análisis

≥98% (HPLC)

formulario

powder

solubilidad

DMSO: ≥10 mg/mL

emisor

GlaxoSmithKline

temp. de almacenamiento

2-8°C

cadena SMILES

CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3

InChI

1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)

Clave InChI

YASAKCUCGLMORW-UHFFFAOYSA-N

Información sobre el gen

human ... PPARG(5468)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Rosiglitazone is a member of the thiazolidinedione family. It effectively lowers glucose levels by enhancing the response of target cells to insulin, without causing increased stimulation and release of insulin by the pancreatic beta cells. Rosiglitazone functions by activating the nuclear peroxisome proliferator-activated (PPAR) receptor gamma, which plays a key role in regulating adipogenesis, glucose metabolism, and genetic networks. It exhibits high potency as a thiazolidinedione, with a binding affinity for PPAR-gamma that is 30-fold higher than pioglitazone. Furthermore, it increases insulin-stimulated IRS-1/2 in skeletal muscle and adipose tissue, leading to the expression of the GLUT4 glucose transporter.

Aplicación

Rosiglitazone has been used:
  • as a medium constituent for adipocyte differentiation
  • in the cell proliferation assay in human colonic carcinoma cell lines
  • for Bcl-2-like protein 13 (Bcl2l13) expression in adipocytes
  • as a peroxisome proliferator-activated receptor gamma (PPARγ) ligand

Acciones bioquímicas o fisiológicas

Rosiglitazone is a potent agonist for PPARγ with an EC50 of 43 nM for the human receptor. It is antidiabetic, working as an insulin sensitizer by binding to the PPARγ receptors in fat cells and making the cells more responsive to insulin.

Características y beneficios

This compound is a featured product for ADME Tox and Gene Regulation research. Discover more featured ADME Tox and Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the AMPKs and Nuclear Receptors (PPARs) pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

A novel role for Bcl2l13 in promoting beige adipocyte biogenesis
Ju L, et al.
Biochemical and Biophysical Research Communications, 506(3), 485-491 (2018)
Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells
Lau MF, et al.
EXCLI Journal, 17, 186-186 (2018)
Siyu Xie et al.
Nutrients, 11(7) (2019-07-22)
Promoting white-to-beige adipocyte transition is a promising approach for obesity treatment. Although Liensinine (Lie), a kind of isoquinoline alkaloid, has been reported to affect white-to-beige adipocyte transition, its effects on inhibiting beige adipocytes recovering to white adipocytes and maintaining the
María Isabel Cuartero et al.
Stroke, 44(12), 3498-3508 (2013-10-19)
Neutrophils have been traditionally recognized as major mediators of a deleterious inflammatory response in acute ischemic stroke, but their potential as a therapeutic target remains unexplored. Recent evidence indicates that neutrophils may acquire different phenotypes and contribute to resolution of
Diego Caprioglio et al.
Planta medica, 85(11-12), 981-986 (2019-04-02)
A general protocol for the selective mono-O-methylation of resorcinyl phytocannabinoids was developed. The availability of semisynthetic monomethyl analogues of cannabigerol, cannabidiol, and cannabidivarin (1A: -3A: , respectively) made it possible to quantify these minor phytocannabinoids in about 40 different chemotypes

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico